Abstract:Introduction Since its first publication in 1977, the World Health Organization's (WHO) Model List of Essential Medicines (EML) has guided the national procurement of medicines deemed essential to inform public health policy worldwide. Aiming to include the most effective, safe, and cost-effective medicines for priority conditions, WHO updates the EML every two years. However, over the past 45 years, updates to the mental health section of the EML have been infrequent, mostly involving the addition of individual medicines. A comprehensive revision of the entire section was never attempted. Objectives The aim of this project was to update the mental health section of the EML to identify the most effective and safest medicines for mental disorders in the light of the most up-to-date evidence base. Methods A series of nine evidence-based applications were submitted to the WHO Expert Committee on the Selection and Use of Essential Medicines in December 2022, recommending a substantial revision of the entire mental health section. Results All of our applications were accepted by the WHO Expert Committee. For psychotic disorders, aripiprazole, olanzapine, paliperidone, and quetiapine were added as therapeutic alternatives to risperidone; short-acting intramuscular chlorpromazine was replaced by short-acting intramuscular olanzapine; first-generation antipsychotics were limited to oral haloperidol and chlorpromazine. For bipolar disorder, the list now includes second-generation antipsychotics such as quetiapine, aripiprazole, olanzapine, and paliperidone. Tricyclic antidepressants for depressive disorders were limited to amitriptyline alone. Treatment options for anxiety and obsessive-compulsive disorder are now expanded to include SSRIs. For anxiety disorders, diazepam and lorazepam became the only benzodiazepines recommended, with the specific caveat that they should only be used for short-term emergency treatment of acute and severe anxiety symptoms. Finally, chlorpromazine and haloperidol are no longer considered essential medications for psychotic disorders in children under 13 years of age. Conclusions The WHO released the 23 rd EML in July 2023. After decades of minimal and inconsistent updates, groundbreaking changes have been made to its mental health section. The updated mental health section provides a compelling opportunity to improve the quality of medicine selection at the country level, with the goal of increasing the availability of the safest and most effective psychotropic medicines worldwide. Disclosure of Interest None Declared

Evaluation of the Drugs for Serious Mental Illness in National Essential Medicine List of 2012 Edition Using Pharmacoeconomics Method

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Evidence-based Research on the Selection Method System for China's Essential Medicine List

Economic evaluations of novel antipsychotic medications: a literature review

Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders

Investigation and analysis on the frequency of anti -psychotropic drugs of all grades of mental health institutions in Hebei

Cost-effectiveness of Long-Acting Risperidone Injection Versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China.

Cost-Effectiveness Analysis of Amisulpride and Olanzapine for Patients with Schizophrenia in China

A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia

Trends of Antipsychotic Drugs Use in Schizophrenia Patients from Hebei Province

Antipsychotic Medications in Major Depression and the Association with Treatment Satisfaction and Quality of Life: Findings of Three National Surveys on Use of Psychotropics in China Between 2002 and 2012

Investigation of Clinical Application of Antipsychotic Drugs for Psychiatric Inpatients

Analysis of Drug Utilization in Inpatients with Schizophrenia in Our Hospital During Nov. 2007~nov. 2008

Comparative Efficacy and Safety Between Amisulpride and Olanzapine in Schizophrenia Treatment and a Cost Analysis in China: a Systematic Review, Meta-Analysis, and Cost-Minimization Analysis.

Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis

Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis

Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.

1295-P: Economic Evaluation of Drug Combination Strategy for Type 2 Diabetes in China

Investigation and Analysis of the Use of National Essential Medicines in Outpatient Department of Our Hospi-tal in 2013

Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence

A Survey of Availability, Price and Affordability of Essential Medicines from 2011 to 2016 in Chinese Secondary and Tertiary Hospitals